P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HOD...

por Hernandez-Ilizaliturri, F. J., Kuruvilla, J., Christian, B. A., Flinn, I. W., Assouline, S. E., Ulrickson, M. L., Landsburg, D. J., Stuart, M., Lowman, H., Levin, N., Maetzel, D., Viller, N. N., MacLaren, A.
Publicado 2022